A Look At iRhythm Holdings (IRTC) Valuation After Recent Share Price Weakness

Event context and recent share performance

iRhythm Holdings (IRTC) has drawn investor attention after a sharp move in its shares, with the price at $118.14 and recent returns showing a 22% decline over the past month and a 34% decline over the past 3 months.

See our latest analysis for iRhythm Holdings.

Despite the recent 22% 1 month share price decline and 34% 3 month share price decline, iRhythm Holdings still shows an 11.6% 1 year total shareholder return. This suggests momentum has faded in the short term while longer term holders remain positive overall.

If you are looking beyond a single healthcare name and want more ideas tied to medical technology and data driven care, it can be useful to scan for 36 healthcare AI stocks

With the shares down sharply in recent months but still showing an 11.6% 1 year total return and trading below some estimated value markers, the question now is whether iRhythm is mispriced or if the market already reflects its future growth.

Most Popular Narrative: 44% Undervalued

iRhythm Holdings last closed at $118.14, while the most followed narrative places fair value at $211, suggesting a wide gap between price and modelled worth.

Investment in the Zio ecosystem, including next generation patches, enhanced form factors, and AI powered analytics is improving product differentiation, diagnostic yield, and workflow efficiency. This may lead to higher gross margins and operating leverage as software and data become a larger component of the business.

Read the complete narrative.

Curious what kind of revenue runway, margin lift and future earnings multiple are baked into that fair value? The full narrative lays out a detailed playbook.

Result: Fair Value of $211 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on regulatory issues and sector wide multiple compression not worsening, since tougher audits or lower reimbursement assumptions could quickly pressure those fair value inputs.

Find out about the key risks to this iRhythm Holdings narrative.

Another View: What The Sales Multiple Is Saying

The narrative and fair value estimate point to iRhythm Holdings looking undervalued, yet the current P/S ratio of 5.1x tells a different story. It sits above the US Medical Equipment industry average of 2.7x, the peer average of 4.5x, and a fair ratio estimate of 3.9x.

That gap suggests investors are already paying a premium for future growth. This raises the question of whether the discount to fair value is as clear cut as it first appears, or whether there is more valuation risk priced in than the models imply.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If the mixed signals on price, growth expectations and valuation leave you uncertain, that is a useful starting point, not a problem. Move quickly from headlines to hard numbers and sentiment checks by weighing the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock when there are focused lists that can quickly surface other opportunities you might wish you had found earlier.

• Target high quality names that look attractively priced by scanning the 55 high quality undervalued stocks before the market reassesses them.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (39 results) so potential weak links do not sit unnoticed in your portfolio.
• Get ahead of the crowd by checking the screener containing 26 high quality undiscovered gems and spot compelling stories before they are widely talked about.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com